Metabomed, ChanBio join Merck Serono Israel BioincubatorNov. 28, 2013
Metabomed and ChanBio have joined the Merck Serono Israel Bioincubator in Yavne. They join Neviah Genomics Ltd., the first company to join the incubator, in which Merck Serono invested €10 million.
Metabomed, founded by researchers at Tel Aviv University and the Technion Israel Institute of Technology, is conducting research on cancer metabolism and computational biology.
Earlier this month, Merck KgaA increased its investment inQlight Nanotech and signed a memorandum of understanding with Kadimastem, a developer of human pluripotent stem cell-related products.
The innovative landscape of Israel fits in perfectly with our ‘Living Innovation’ claim,” said Merck head of pharmaceuticals Stefan Oschmann. “In Israel, we not only have a past which has led to some of Merck’s most important products like Rebif and Erbitux, but also a promising future because we continue to find very interesting and cutting-edge science and the support here in Israel to translate that science into products."
For the full Globes news item click here.